Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04723004 | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | completed | Phase 3 | 326 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT05301842 | Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC(EMERALD-3) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 22 | Jul 13, 2026 |
| clinicaltrials |
| NCT06109779 | Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | active not recruiting | Phase 3 | 760 | AstraZenecaINDUSTRY | 21 | Jul 10, 2026 | clinicaltrials |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer | recruiting | Phase 3 | 106 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | active not recruiting | Phase 3 | 594 | AstraZenecaINDUSTRY | 19 | Jul 9, 2026 | clinicaltrials |
| NCT07692152 | Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma | recruiting | Phase 3 | 350 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03879109 | Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer(GRECCAR15) | completed | Phase 3 | 58 | University Hospital, BordeauxOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07518147 | A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment | recruiting | Phase 3 | 438 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07689539 | Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 3 | 360 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 8, 2026 | clinicaltrials |
| NCT04523493 | Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC | active not recruiting | Phase 3 | 530 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 5 | Jul 6, 2026 | clinicaltrials |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma(FIRST-308) | active not recruiting | Phase 3 | 200 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 13 | Jul 6, 2026 | clinicaltrials |
| NCT03186898 | Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer | active not recruiting | Phase 3 | 115 | NRG OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05710406 | Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | active not recruiting | Phase 2 / Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07549399 | SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC(CRITⅡ) | recruiting | Phase 3 | 204 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
| NCT03051464 | Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery(MORPHEUS) | recruiting | Phase 2 / Phase 3 | 131 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 2 | Jun 30, 2026 | clinicaltrials |
| NCT06507371 | Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer(mRCAT-III) | active not recruiting | Phase 3 | 170 | Sir Run Run Shaw HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06794086 | SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases(SPARKLE-L) | recruiting | Phase 3 | 24 | Jun HuangOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02945566 | Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?(STAR-TREC) | active not recruiting | Phase 2 / Phase 3 | 380 | University of BirminghamOTHER | 5 | Jun 29, 2026 | clinicaltrials |
| NCT05557838 | Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC(TREMENDOUS) | active not recruiting | Phase 3 | 214 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05144854 | A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) | active not recruiting | Phase 3 | 626 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 3 | Jun 25, 2026 | clinicaltrials |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas(CIME) | recruiting | Phase 3 | 132 | Centre Leon BerardOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07669454 | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.(NuvastaticTM) | recruiting | Phase 3 | 250 | Natureceuticals Sdn BhdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 3 | 356 | National Cancer Institute (NCI)NIH | 3 | Jun 24, 2026 | clinicaltrials |
| NCT00079274 | Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | completed | Phase 3 | 3,397 | National Cancer Institute (NCI)NIH | 3 | Jun 23, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04102098 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation(IMbrave050) | completed | Phase 3 | 668 | Hoffmann-La RocheINDUSTRY | 26 | Jun 18, 2026 | clinicaltrials |
| NCT07656376 | Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation | not yet recruiting | Phase 2 / Phase 3 | 465 | Jiangxi Kvvit Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 18, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer(ESCC-PT) | not yet recruiting | Phase 2 / Phase 3 | 90 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT06642844 | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL) | recruiting | Phase 3 | 244 | University Hospital, ToursOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk(ASPIK French) | active not recruiting | Phase 3 | 264 | University Hospital, RouenOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05593458 | Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1(TACTIC) | recruiting | Phase 3 | 190 | Zhejiang UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06446557 | De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer(DIAMOND) | not yet recruiting | Phase 3 | 408 | University Hospital, RouenOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06900543 | Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere(CHEERS) | active not recruiting | Phase 3 | 108 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT02562755 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone(PHOCUS) | completed | Phase 3 | 459 | SillaJen, Inc.INDUSTRY | 16 | Jun 8, 2026 | clinicaltrials |
| NCT06783491 | Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer(FOXHIPECT4) | recruiting | Phase 3 | 1,083 | Maimónides Biomedical Research Institute of CórdobaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | recruiting | Phase 3 | 288 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT06914011 | Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma(MRD2START) | not yet recruiting | Phase 3 | 172 | Asan Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT07621601 | A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 3 | 494 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jun 2, 2026 | clinicaltrials |
| NCT00002968 | Edrecolomab in Treating Patients With Stage II Colon Cancer | completed | Phase 3 | 2,100 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | active not recruiting | Phase 3 | 490 | Daiichi SankyoINDUSTRY | 24 | May 27, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials